Vital hepatitis reactivation with anti-tumor necrosis factor-alpha: What do we know?

Israel Medical Association Journal

Volumn 15, Issue 6, 2013, Pages 298-300

  Zuckerman, Eli ^a,b  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anti tumor necrosis factor alpha (anti TNF ); Hepatitis b virus (HBV); Hepatitis c virus (HCV); Immunosuppression; Preemptive treatment; Reactivation

Indexed keywords

CORTICOSTEROID; LAMIVUDINE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIVIRAL THERAPY; CANCER CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); EDITORIAL; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; LIVER FUNCTION TEST; MASS SCREENING; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; ORGAN TRANSPLANTATION; PREVALENCE; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); VIRAL CLEARANCE; VIRUS LOAD; VIRUS REACTIVATION;

CROHN DISEASE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 84879535886     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (19)

1. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006; 4: 1076-1081.
2. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90 (7): 1306-1311.
3. Fuchs I, Abu-Shakra M, Sikuler E. Hepatitis B and C reactivation with anti-tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations. IMAJ 2013; 15: 303-307.
4. Aslanidis S, Vassilladis T, Pyrpasopoulou A, Douloumpakas I, Zamboulis C. Inhibition of TNFα does not induce viral reactivation in patients with hepatitis C infection: two cases. Clin Rheumatol 2007; 26: 261-264.
5. Vauloup C, Krzysiek R, Greangeot-Keros L, et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006; 17: 290-293.
6. Brunasso A, Puntoni M, Guilia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology 2011; 50: 1700-1711.
7. Yeao W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapywith or without rituximab. J Clin Oncol 2009; 27 (4): 605-611.
8. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365.
9. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000; 223: 241-257.
10. Stine J, Khokhar O, Charalambopoulos J, Shaunmugam V, Lewis J. Rheumatologists' awareness of screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res 2010; 62: 704-711.
11. Lok A, McMahon B. AASLD Practice Guidelines Update. Chronic Hepatitis B: Update 2009. Hepatology 2009; 5 (3): 1-36.
12. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis G, Manolakopoulos S, Koskinas J. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69: 1352-1355.
13. Xunrong L, Yan A, Liang R, Lau G. Hepatitis B virus reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. Rev Med Virol 2001; 11: 287-299.
14. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Hematol 2007; 136: 699-712.
15. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy [Review]. Ann Intern Med 2008; 148 (7): 519-528.
16. Zingarelli S, Airo P, Frassi M, Bazzani, Scarsi M, Puoti M. Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo 2008; 60: 22-27.
17. Esteve M, Loras C, Gonzalex-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007; 13: 1450-1451.
18. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008; 2 (2): 152-162.
19. Cassano N, Mastrandrea V, Principi M, et al. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic arthropathy. J Biol Regul Homeost Agents 2011; 25 (2): 285-289.